Designing adverse event forms for real-world reporting: Participatory research in uganda

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Davies, Emma C ^a   Chandler, Clare I R ^b   Innocent, Simeon H S ^c   Kalumuna, Charles ^d   Terlouw, Dianne J ^a   Lalloo, David G ^a   Staedke, Sarah G ^b   Haaland, Ane ^e  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Uganda Malaria Surveillance Project   (Uganda)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ANTIINFECTIVE AGENT; ARTEMISININ DERIVATIVE;

ARTICLE; CONCEPTUAL FRAMEWORK; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INFORMATION PROCESSING; MEDICAL PRACTICE; PARTICIPATORY RESEARCH; POSTMARKETING SURVEILLANCE; PRETEST POSTTEST DESIGN; ROLE PLAYING; STUDY DESIGN; UGANDA; WORKSHOP; DRUG COMBINATION; DRUG MONITORING; MALARIA; METHODOLOGY; REPRODUCIBILITY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFECTIVE AGENTS; ARTEMISININS; COMMUNITY-BASED PARTICIPATORY RESEARCH; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; PHARMACOVIGILANCE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; UGANDA;

EID: 84859073128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032704     Document Type: Article

References (31)

1. Talisuna AO, Staedke SG, D'Alessandro U, (2006) Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J 5: 50.
2. Stergachis A, Bartlein RJ, Dodoo A, Nwokike J, Kachur SP, (2010) A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals. Malar J 9: 148.
3. Kuemmerle A, Dodoo AN, Olsson S, Van Erps J, Burri C, et al. (2011) Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring. Malar J 10: 57.
4. European Medicines Agency (1995) ICH Topic E 2 A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Available: http://www.emea.europa.eu/pdfs/human/ich/037795en.pdf. Accessed 2011 Apr 29.
5. Medicines and Healthcare Products Regulatory Agency Yellow Card Scheme. Available: http://yellowcard.mhra.gov.uk/the-yellow-card-scheme/. Accessed 2011 Apr 30.
6. Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, et al. (2008) Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health.
7. Etkin NL, (1992) Side-Effects- Cultural Constructions and Reinterpretations of Western Pharmaceuticals. Medical Anthropology Quarterly 6: 99-113.
8. Kamat VR, (2009) Cultural interpretations of the efficacy and side effects of antimalarials in Tanzania. Anthropology & Medicine 16: 293-305.
9. Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, et al. (2008) Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J 7: 107.
10. Mehta U, Durrheim D, Mabuza A, Blumberg L, Allen E, et al. (2007) Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa. Drug Saf 30: 899-910.
11. Cornwall A, Jewkes R, (1995) What is participatory research? Soc Sci Med 41: 1667-1676.
12. Haaland A, (1984) Pretesting communication materials with special emphasis on child health and nutrition education: a manual for trainers and supervisors Rangoon, Burma UNICEF.
13. Chetley A, Hardon A, Hodgkin A, Haaland A, Fresle D, (2007) How to Improve the Use of Medicines by Consumers Geneva World Health Organisation.
14. Haaland A, Molyneux CS, Marsh V, (2006) Quality information in field research: Training manual on practical communication skills for field researchers and project personnel. World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases. Available: http://whqlibdoc.who.int/hq/2006/TDR_IRM_PCT_05.1_eng.pdf. Accessed 2012 Feb 04.
15. Van der Geest S, Whyte SR, (1989) The Charm of Medicines: Metaphors and Metonyms. Medical Anthropology Quarterly 3: 345-367.
16. Haaland A, (2001) Reporting with Pictures. A concept paper for researchers and health policy decision-makers Geneva UNDP/WOrld Bank/WHO Special Programme for Research and Training in Tropical Diseases.
17. Charles C, Gafni A, Whelan T, (1999) Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 49: 651-661.
18. Mead N, Bower P, (2000) Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med 51: 1087-1110.
19. Ajayi IO, Oladepo O, Falade CO, Bamgboye EA, Kale O, (2008) The development of a treatment guideline for childhood malaria in rural Southwest Nigeria using participatory approach. Patient Educ Couns.
20. UNDP/World Bank/WHO (1996) Community Directed Treatment with ivermectin. Report of a Multi-Country study. Special Programme for Research and Training in Tropical Diseases (TDR) in collaboration with the Onchocerciasis Control Programme in West Africa (OCP) and the African Programme for Onchocerciasis Control (APOC).
21. World Health Organisation (2007) A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva. Available: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/handbook_antimalarialpharmvigilance.pdf. Accessed 2011 Apr 30.
22. Edwards IR, (2008) Controlled trials and risk of harm. Drug Saf 31: 961-963.
23. WHOMMV (2009) Pharmacovigilance guidance for countries participating in AMFm Phase 1. WHO-MMV joint technical consultation on active pharmacovigilance monitoring with a special focus on AMFm Geneva World Health Organisation & Medicines for Malaria Venture.
24. Blenkinsopp A, Wilkie P, Wang M, Routledge PA, (2007) Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 63: 148-156.
25. Basch E, (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362: 865-869.
26. Oshikoya KA, Senbanjo IO, Njokanma OF, (2009) Parental reporting of suspected adverse drug reactions in children in Lagos, Nigeria. Arch Dis Child 94: 469-473.
27. Mehta U, Allen E, Barnes KI, (2010) Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria. Expert Rev Clin Pharmacol 3: 509-525.
28. Bhattacharyya K, Winch P, LeBan K, Tien M, (2001) Community Health Worker Incentives and Disincentives: How They Affect Motivation, Retention, and Sustainability Arlington, Virginia Published by the Basic Support for Institutionalizing Child Survival Project (BASICS II) for USAID.
29. Rowe SY, Olewe MA, Kleinbaum DG, McGowan JE Jr, McFarland DA, et al. (2007) Longitudinal analysis of community health workers' adherence to treatment guidelines, Siaya, Kenya, 1997-2002. Trop Med Int Health 12: 651-663.
30. Kelly JM, Osamba B, Garg RM, Hamel MJ, Lewis JJ, et al. (2001) Community health worker performance in the management of multiple childhood illnesses: Siaya District, Kenya, 1997-2001. Am J Public Health 91: 1617-1624.
31. Das J, Hammer J, Sanchez-Paramo C, (2011) The Impact of Recall Periods on Reported Morbidity and Health Seeking Behaviour. World Bank, Development Research Group.